Immune checkpoints (ICs) have pivotal roles in regulating immune responses. The inhibitory ICs in the tumor microenvironment (TME) have been implicated in the immune evasion of tumoral cells. Therefore, identifying and targeting these inhibitory ICs might be critical for eliminating tumoral cells. V-domain immunoglobulin suppressor of T cell activation (VISTA) is a novel inhibitory IC that is expressed on myeloid cells, lymphoid cells, and tumoral cells; therefore, VISTA can substantially regulate innate and adaptive anti-tumoral immune responses. Besides, growing evidence indicates that VISTA blockade can enhance the sensitivity of tumoral cells to conventional IC-based immunotherapy, e.g., cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors. In this regard, the current study aimed to review the current evidence about the structure and expression pattern of VISTA, its role in TME, the clinicopathological significance of VISTA, and its prognostic values in various cancers. Besides, this review intended to collect the lessons from the recent pre-clinical and clinical studies and propose a strategy to overcome tumor immune-resistance states.

The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead / Hosseinkhani, Negar; Derakhshani, Afshin; Shadbad, Mahdi Abdoli; Argentiero, Antonella; Racanelli, Vito; Kazemi, Tohid; Mokhtarzadeh, Ahad; Brunetti, Oronzo; Silvestris, Nicola; Baradaran, Behzad. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - 12:(2021), pp. 67618101-67618110. [10.3389/fimmu.2021.676181]

The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead

Racanelli, Vito;
2021-01-01

Abstract

Immune checkpoints (ICs) have pivotal roles in regulating immune responses. The inhibitory ICs in the tumor microenvironment (TME) have been implicated in the immune evasion of tumoral cells. Therefore, identifying and targeting these inhibitory ICs might be critical for eliminating tumoral cells. V-domain immunoglobulin suppressor of T cell activation (VISTA) is a novel inhibitory IC that is expressed on myeloid cells, lymphoid cells, and tumoral cells; therefore, VISTA can substantially regulate innate and adaptive anti-tumoral immune responses. Besides, growing evidence indicates that VISTA blockade can enhance the sensitivity of tumoral cells to conventional IC-based immunotherapy, e.g., cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors. In this regard, the current study aimed to review the current evidence about the structure and expression pattern of VISTA, its role in TME, the clinicopathological significance of VISTA, and its prognostic values in various cancers. Besides, this review intended to collect the lessons from the recent pre-clinical and clinical studies and propose a strategy to overcome tumor immune-resistance states.
2021
Hosseinkhani, Negar; Derakhshani, Afshin; Shadbad, Mahdi Abdoli; Argentiero, Antonella; Racanelli, Vito; Kazemi, Tohid; Mokhtarzadeh, Ahad; Brunetti, Oronzo; Silvestris, Nicola; Baradaran, Behzad
The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead / Hosseinkhani, Negar; Derakhshani, Afshin; Shadbad, Mahdi Abdoli; Argentiero, Antonella; Racanelli, Vito; Kazemi, Tohid; Mokhtarzadeh, Ahad; Brunetti, Oronzo; Silvestris, Nicola; Baradaran, Behzad. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - 12:(2021), pp. 67618101-67618110. [10.3389/fimmu.2021.676181]
File in questo prodotto:
File Dimensione Formato  
2021 Front Immunol_VISTA.pdf

accesso aperto

Tipologia: Versione editoriale (Publisher’s layout)
Licenza: Creative commons
Dimensione 823.71 kB
Formato Adobe PDF
823.71 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11572/386858
Citazioni
  • ???jsp.display-item.citation.pmc??? 19
  • Scopus 33
  • ???jsp.display-item.citation.isi??? 27
social impact